Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
AVITA Medical reports developments in therapeutic acute wound care, led by the RECELL platform for Spray-On Skin used in burn and trauma wounds. Company news commonly covers FDA-cleared wound-care indications, RECELL GO automation, international regulatory clearances, and the U.S. commercial portfolio that includes Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix.
Updates also include clinical data presentations, BARDA emergency-preparedness agreements, quarterly financial results, investor-conference participation, and board or executive governance changes. The recurring news themes connect AVITA Medical's product platform with acute burn care, trauma wound treatment, commercialization, reimbursement, and capital resources.
AVITA Therapeutics (NASDAQ: RCEL) has announced a preclinical research collaboration with Houston Methodist Research Institute to explore the combination of its Spray-On Skin™ Cells with advanced cellular aging reversal technologies. This initiative aims to create a novel method for skin rejuvenation, with potential applications in scar revision and wound healing. The partnership includes an exclusive licensing option for related technologies and anticipates an 18-month research program aimed at regulatory submission for Investigational New Drug applications.
AVITA Therapeutics (NASDAQ: RCEL) announced that David McIntyre will resign as Chief Financial Officer effective November 23, 2020, to pursue opportunities in New Jersey. McIntyre will assist the company until December 31, 2020, ensuring a smooth transition to Sean Ekins, the current Vice President of Finance, who will take over CFO responsibilities starting November 9, 2020. AVITA will begin an external search for a new CFO. The company is known for its RECELL System, a treatment for burns that was FDA approved in 2018 and has been effectively used in over 8,000 patients globally.
AVITA Therapeutics, Inc. (NASDAQ: RCEL) has announced a schedule change for its adjourned 2020 Annual Stockholder Meeting due to daylight savings adjustments. The meeting will now take place at 8:00 am AEDT on November 10, 2020, which remains at 1:00 pm Pacific Time on November 9, 2020. Stockholders are advised to read the definitive proxy statement filed with the SEC for important voting information. The RECELL System, the company’s first U.S. product, is notable for its innovative approach to acute thermal burn treatment.
AVITA Therapeutics, Inc. (NASDAQ: RCEL) announced a change in the date of its Q1 2021 earnings release and conference call to November 10, 2020. The conference call will occur at 1:30 p.m. Pacific time, where the company will discuss financial results and recent highlights. AVITA focuses on regenerative medicine, developing autologous skin restoration technologies like the RECELL System, approved by the FDA for treating acute thermal burns. The company emphasizes its innovative treatment solutions and aims to address unmet medical needs in burns and chronic wounds.
AVITA Therapeutics, Inc. (NASDAQ: RCEL) announced the adjournment of its 2020 Annual Stockholder Meeting originally scheduled for October 29, 2020, due to a lack of quorum. Only 49% of shares were represented, falling short of the required 50% majority. The meeting has been rescheduled for November 9, 2020, to gather more votes. During this time, the company is actively soliciting votes with the help of a proxy solicitor. Stockholders who have not yet voted are encouraged to do so by November 5, 2020. The company may incur additional costs if a quorum is not achieved at the adjourned meeting.
AVITA Therapeutics (NASDAQ: RCEL) announced its participation in two upcoming investor conferences: the Oppenheimer Fall MedTech Summit on November 12, 2020, and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 8:30 a.m. ET. The company specializes in regenerative medicine, focusing on skin restoration using its patented RECELL System, approved by the FDA in September 2018 for treating acute thermal burns. AVITA is actively addressing various unmet medical needs in burns, chronic wounds, and aesthetics.
AVITA Therapeutics (NASDAQ: RCEL) announced its plans to release Q1 2021 financial results on November 11, 2020, after market close. A conference call to discuss these results will follow at 1:30 PM Pacific time. The company focuses on regenerative medicine, particularly with its RECELL® System for treating burns, which received FDA approval in September 2018. This system significantly reduces donor skin requirements and has been used in over 8,000 patients worldwide.